Opendata, web and dolomites

ARGONAUT SIGNED

ARGONAUT: from the synthesis of gAnglioside tumouR antiGens to a platfOrm for caNcer Active immUnoTherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ARGONAUT" data sheet

The following table provides information about the project.

Coordinator
DANMARKS TEKNISKE UNIVERSITET 

Organization address
address: ANKER ENGELUNDSVEJ 1 BYGNING 101 A
city: KGS LYNGBY
postcode: 2800
website: www.dtu.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 207˙312 €
 EC max contribution 207˙312 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DANMARKS TEKNISKE UNIVERSITET DK (KGS LYNGBY) coordinator 207˙312.00

Map

 Project objective

Immunotherapy is currently revolutionizing cancer therapy by harnessing the power of the innate and adaptive immune system against cancer cells, thus providing a more tumour-selective approach in assistance to traditional treatments. The identification of tumour-associated carbohydrate antigens (TACAs), aberrant types of glycans decorating the surface of tumour cells, has paved the way for the development of new types of cancer vaccines. However, while significant progress has been made in this area of research, TACA-based cancer vaccines have not yet reached the clinic. In this context, ARGONAUT will address some limitations that characterize classical approaches in carbohydrate cancer vaccine development, with the overall aim of establishing a strategy to access novel, more effective, and fully synthetic vaccine candidates. ARGONAUT’s journey aims at the preparation of vaccine candidates based on ganglioside-type TACAs (expressed in melanoma, neuroblastoma, and small cell lung cancer) that are easy to formulate, able to elicit a immune response independent from individual polymorphisms, and with better chances to reach the clinical environment. Employing a synthetic carbohydrate chemistry approach, ARGONAUT explores its application as a tool to contribute to H2020 European efforts in cancer research, while providing excellent training in a multidisciplinary and intersectoral environment through a well-implemented work-plan. From another perspective, ARGONAUT’s impact will also benefit from the transfer of knowledge to the host institution with the establishment of a new research line in active cancer immunotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ARGONAUT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ARGONAUT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

DGLC (2019)

Domain-general language control: Evidence from the switching paradigm

Read More  

OSeaIce (2019)

Two-way interactions between ocean heat transport and Arctic sea ice

Read More  

LearningEmotions (2020)

Emotion Recognition: A Statistical Learning Approach

Read More